Liana Moussatos is cautious on OMER’s “unclear” finances despite Wall Street’s enthusiasm for Omidria’s prospective two-year reimbursement extension.
Analyst Cautiously Celebrating Biotech Player’s Stellar Q2 Performance from the Sidelines
Omeros Corporation (NASDAQ:OMER) announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2017, which include: 2Q …
Omeros’ Response to Short Seller Accusations Sends Shares Up
Omeros Corporation (NASDAQ:OMER) shares are on the rise after the drug maker announced that OMS721 has been granted FDA breakthrough therapy designation for the treatment …
Omeros Corporation (NASDAQ:OMER) announced that the FDA has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 …
Omeros Corporation (NASDAQ:OMER) announced completion of the IgA nephropathy cohort and reported additional positive results from the first stage of the company’s Phase …
Drug maker Omeros Corporation (NASDAQ:OMER) delivered solid results for its earnings report for the first quarter of the year 2017. In reaction, Maxim analyst Jason …
Omeros Corporation (NASDAQ:OMER) announced additional positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders, which …
Omeros Corporation (NASDAQ:OMER) announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2016, …
